Abstract:Although breast cancer is by far the most common cancer among all women worldwide, its incidence rates vary substantially in different populations. In the United States, rates are highest among white women, followed by African American (AA) and Hispanic American (HA) women. Among HA women, breast cancer incidence rates are higher among those born in the United States than among first-generation immigrants, who, in turn, have higher rates than their counterparts in their countries of origin. Among foreign-born HA women, breast cancer risk has been shown to increase with the duration of U.S. residency, degree of acculturation, and younger age at migration, underscoring the importance of environmental influence on breast cancer risk. On the other hand, overall breast cancer risk among HA women has been shown to increase with the degree of European contribution to their genetic admixture. Among AA women, a higher proportion of European ancestry has been associated with a less aggressive form of breast cancer (estrogen receptor [ER] positive/progesterone receptor [PR] positive and localized). These observations highlight the need for understanding the population genetic substructure in the evaluation of racial/ ethnic disparities in breast cancer incidence and prognosis. Although breast cancer is more likely to occur in white women, AA and HA breast cancer patients are more likely to die of their disease. The age at onset tends to be earlier in AA and HA women, and these cases tend to have more aggressive histologic characteristics, including the triplenegative breast cancer (TNBC) that lacks expression of ER, PR, and human epidermal growth factor receptor 2 (HER2). Interestingly, limited evidence suggests that TNBC is also overrepresented among Hispanic and African women in their countries of origin. The predisposition to more aggressive tumors likely has contributed to the higher mortality rates among young minority women. However, the poor prognosis of breast cancer among AA and HA women has also been attributed, in part, to inadequate health insurance, limited access to mammography, advanced disease stage at diagnosis, delayed and inadequate treatment, and a high prevalence of comorbidity.

Breast Cancer Risk in Relation to Plasma Metabolites among Hispanic and African American Women

Correction To: Methylseleninic Acid Suppresses Breast Cancer Growth Via the JAK2/STAT3 Pathway

Validation of Plasma Metabolites Associated with Breast Cancer Risk among Mexican Americans.

Author Correction: Synergistic Suppression of Human Breast Cancer Cells by Combination of Plumbagin and Zoledronic Acid in Vitro

Correction: An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Erratum: Reina-Castillón J, Pujol R, López-Sánchez M, et al. Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia. Blood Adv. 2017;1(5):319-329

Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis

Correction: Perceived neighborhood social cohesion and cervical and breast cancer screening utilization among U.S.-born and immigrant women

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Correction to: Depression Induced by Total Mastectomy, Breast Conserving Surgery and Breast Reconstruction: A Systematic Review and Meta-analysis

Corrigendum: Diseases of the musculoskeletal system and connective tissue and risk of breast cancer: mendelian randomization study in European and East Asian populations

Correction: the Hmlh1 −93g>a Polymorphism and Risk of Ovarian Cancer in the Chinese Population

Correction To: Proteogenomic Characterization and Comprehensive Integrative Genomic Analysis of Human Colorectal Cancer Liver Metastasis

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells

Racial/ethnic Disparities in Breast Cancer Risk: Genomics Meets Metabolomics

Correction To: Prophylactic HIPEC with Radical D2 Gastrectomy Improves Survival and Peritoneal Recurrence Rates for Locally Advanced Gastric Cancer: Personal Experience from a Randomized Case Control Study

Correction to: The Effect of Postmastectomy Radiotherapy on Breast Cancer Patients After Neoadjuvant Chemotherapy by Molecular Subtype

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

RETRACTION: CYP2E1 Rsa /Pst polymorphism and lung cancer susceptibility: A meta-analysis involving 10,947 subjects (Retraction of Vol 19, Pg 2136, 2015)